Logo image of AGEN

AGENUS INC (AGEN) Stock Fundamental Analysis

NASDAQ:AGEN - Nasdaq - US00847G8042 - Common Stock - Currency: USD

3.5  +0.59 (+20.27%)

Premarket: 3.61 +0.11 (+3.14%)

Fundamental Rating

1

AGEN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. AGEN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AGEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AGEN has reported negative net income.
AGEN had a negative operating cash flow in the past year.
In the past 5 years AGEN always reported negative net income.
AGEN had negative operating cash flow in 4 of the past 5 years.
AGEN Yearly Net Income VS EBIT VS OCF VS FCFAGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

AGEN's Return On Assets of -100.51% is on the low side compared to the rest of the industry. AGEN is outperformed by 76.51% of its industry peers.
Industry RankSector Rank
ROA -100.51%
ROE N/A
ROIC N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGEN Yearly ROA, ROE, ROICAGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

With an excellent Gross Margin value of 99.53%, AGEN belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
In the last couple of years the Gross Margin of AGEN has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for AGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
AGEN Yearly Profit, Operating, Gross MarginsAGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGEN has been increased compared to 1 year ago.
The number of shares outstanding for AGEN has been increased compared to 5 years ago.
AGEN has a worse debt/assets ratio than last year.
AGEN Yearly Shares OutstandingAGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AGEN Yearly Total Debt VS Total AssetsAGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

AGEN has an Altman-Z score of -15.70. This is a bad value and indicates that AGEN is not financially healthy and even has some risk of bankruptcy.
AGEN has a worse Altman-Z score (-15.70) than 82.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.7
ROIC/WACCN/A
WACC10%
AGEN Yearly LT Debt VS Equity VS FCFAGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

2.3 Liquidity

A Current Ratio of 0.21 indicates that AGEN may have some problems paying its short term obligations.
With a Current ratio value of 0.21, AGEN is not doing good in the industry: 96.44% of the companies in the same industry are doing better.
A Quick Ratio of 0.21 indicates that AGEN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.21, AGEN is doing worse than 96.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
AGEN Yearly Current Assets VS Current LiabilitesAGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

AGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.79%, which is quite impressive.
Looking at the last year, AGEN shows a very negative growth in Revenue. The Revenue has decreased by -33.81% in the last year.
The Revenue has been decreasing by -7.17% on average over the past years.
EPS 1Y (TTM)24.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.54%
Revenue 1Y (TTM)-33.81%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%-67.98%

3.2 Future

The Earnings Per Share is expected to grow by 13.07% on average over the next years. This is quite good.
The Revenue is expected to grow by 21.41% on average over the next years. This is a very strong growth
EPS Next Y61.51%
EPS Next 2Y32.5%
EPS Next 3Y21.06%
EPS Next 5Y13.07%
Revenue Next Year9.3%
Revenue Next 2Y2.15%
Revenue Next 3Y1.7%
Revenue Next 5Y21.41%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AGEN Yearly Revenue VS EstimatesAGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AGEN Yearly EPS VS EstimatesAGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGEN Price Earnings VS Forward Price EarningsAGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGEN Per share dataAGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

AGEN's earnings are expected to grow with 21.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.5%
EPS Next 3Y21.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGENUS INC

NASDAQ:AGEN (5/12/2025, 8:00:00 PM)

Premarket: 3.61 +0.11 (+3.14%)

3.5

+0.59 (+20.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners36.51%
Inst Owner Change-77.49%
Ins Owners1.37%
Ins Owner Change0.47%
Market Cap88.58M
Analysts74.55
Price Target6.12 (74.86%)
Short Float %16.26%
Short Ratio6.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.08%
Min EPS beat(2)-29.49%
Max EPS beat(2)21.32%
EPS beat(4)2
Avg EPS beat(4)-18.03%
Min EPS beat(4)-71.27%
Max EPS beat(4)21.32%
EPS beat(8)4
Avg EPS beat(8)-24.77%
EPS beat(12)7
Avg EPS beat(12)-11.69%
EPS beat(16)9
Avg EPS beat(16)-11.84%
Revenue beat(2)0
Avg Revenue beat(2)-19.77%
Min Revenue beat(2)-26.46%
Max Revenue beat(2)-13.08%
Revenue beat(4)0
Avg Revenue beat(4)-33.65%
Min Revenue beat(4)-62.51%
Max Revenue beat(4)-13.08%
Revenue beat(8)2
Avg Revenue beat(8)-7.69%
Revenue beat(12)6
Avg Revenue beat(12)10.65%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)-14.29%
PT rev (3m)-25%
EPS NQ rev (1m)-3.44%
EPS NQ rev (3m)13.35%
EPS NY rev (1m)0%
EPS NY rev (3m)43.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)55.61%
Revenue NY rev (1m)10.23%
Revenue NY rev (3m)-13.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.86
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.68
EYN/A
EPS(NY)-4.11
Fwd EYN/A
FCF(TTM)-6.28
FCFYN/A
OCF(TTM)-6.26
OCFYN/A
SpS4.09
BVpS-12.9
TBVpS-13.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100.51%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.53%
FCFM N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.32%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -15.7
F-Score2
WACC10%
ROIC/WACCN/A
Cap/Depr(3y)280.5%
Cap/Depr(5y)277.58%
Cap/Sales(3y)20.35%
Cap/Sales(5y)15.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.54%
EPS Next Y61.51%
EPS Next 2Y32.5%
EPS Next 3Y21.06%
EPS Next 5Y13.07%
Revenue 1Y (TTM)-33.81%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%-67.98%
Revenue Next Year9.3%
Revenue Next 2Y2.15%
Revenue Next 3Y1.7%
Revenue Next 5Y21.41%
EBIT growth 1Y22.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.17%
EBIT Next 3Y-10.15%
EBIT Next 5Y-10.98%
FCF growth 1Y32.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.39%
OCF growth 3YN/A
OCF growth 5YN/A